Abbvie Inc

NYSE: ABBV
$183.09
+$1.95 (+1.1%)
Closing Price on November 27, 2024

ABBV Articles

AbbVie shares dipped on Wednesday after the company gave a less than impressive update from its late-stage lymphoma trial.
Here 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates in July.
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Analysts at Jefferies have come up with a list of four pharmaceuticals stocks that may be good investments for a time of uncertainty in global markets.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Dana, Humana, International Paper, Navistar, Southwest Airlines and Tesla.
The top analyst upgrades, downgrades and other research calls from Wednesday include AbbVie, Apple, Broadcom, Exxon Mobil, Fabrinet, HP, Match and Target.
The May 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The April 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
AbbVie is trying one of the older and less-used efforts to drive its share price back up: a modified Dutch tender auction.
The April 13 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
24/7 Wall St. has put together a preview of AbbVie, Eli Lilly and some of the other top pharma and biotech companies reporting their latest quarterly results in the coming week.
Rheumatoid arthritis is an autoimmune disease that attacks tissues within the joints, and it is a major target of U.S. and foreign biotechnology and pharmaceutical companies.
The March 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The March 15 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.